Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Ardent Health Partners, Inc. (ARDT – Research Report), retaining the price target of $21.00.
Whit Mayo has given his Buy rating due to a combination of factors that highlight the potential for Ardent Health Partners, Inc. to perform well in the future. One of the key reasons for this rating is the adjustment in the quarterly earnings forecast to better reflect the seasonality and timing of certain funds, specifically the DPP funds in New Mexico. This adjustment aligns with the company’s management commentary and ensures a more accurate representation of the company’s financial health.
Additionally, Mayo maintains confidence in the company’s long-term performance, as evidenced by the unchanged full-year EBITDA forecast for 2025 and the consistent price target of $21. The decision to keep the EBITDAR-NCI forecasts steady for 2025 and 2026 further supports the positive outlook. These factors, combined with a stable financial structure and alignment with management’s guidance, underpin Mayo’s Buy rating for Ardent Health Partners, Inc.
According to TipRanks, Mayo is a 4-star analyst with an average return of 3.2% and a 48.56% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Pediatrix Medical Group, Ardent Health Partners, Inc., and Acadia Healthcare.